While etoposide is an effective topoisomerase II inhibitor with proven anticancer activity, its role in cervical cancer remains adjunctive rather than primary. Combination-based strategies and advanced drug-delivery systems hold promise for improving its clinical utility. Continued research is essential to overcome resistance and toxicity, potentially expanding the therapeutic relevance of etoposide in cervical cancer management.
Kotian et al. (Sun,) studied this question.